Literature DB >> 10792339

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study.

S Wild1, T Pierpoint, P McKeigue, H Jacobs.   

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) is associated with higher prevalence of cardiovascular risk factors but the relative prevalence of cardiovascular disease in women with PCOS has not previously been reported. We have compared cardiovascular mortality and morbidity in middle-aged women previously diagnosed with PCOS and age-matched control women.
DESIGN: A retrospective cohort study of women diagnosed with PCOS in the United Kingdom before 1979. PATIENTS: Seventy cohort members died before 31 March 1999. Morbidity data were collected from 319 women with PCOS and 1060 age-matched control women. Sixty-one women with PCOS and 63 control women attended a clinical examination. MEASUREMENTS: Data were collected from death certificates, general practitioners' records and questionnaires with measurement of cardiovascular risk factors in a subsample of questionnaire respondents.
RESULTS: All-cause and cardiovascular mortality in the cohort were similar to women in the general population (standardized mortality ratios (95% CI): 93 (72-117) and 78 (45-124), respectively). Women with PCOS had higher levels of several cardiovascular risk factors: diabetes (P = 0.002) hypertension (P = 0.04), hypercholesterolaemia (P < 0.001), hypertriglyceridaemia (P = 0.02) and increased waist:hip ratio (P = 0.004). After adjustment for BMI, odds ratios (OR) were 2.2 (0.9-5. 2) for diabetes, 1.4 (0.9-2.0) for hypertension and 3.2 (1.7-6.0) for hypercholesterolaemia. A history of coronary heart disease (CHD) was not significantly more common in women with PCOS (crude OR (95%CI) 1.5 (0.7-2.9)) but the crude OR for cerebrovascular disease was 2.8 (1.1-7.1).
CONCLUSION: At long-term follow-up, a history of nonfatal cerebrovascular disease and cardiovascular risk factors including diabetes are more prevalent among women with polycystic ovary syndrome. Morbidity and mortality from of coronary heart disease among women with polycystic ovary syndrome is not as high as previously predicted. This finding challenges our understanding of the aetiology of coronary heart disease in women.

Entities:  

Mesh:

Year:  2000        PMID: 10792339     DOI: 10.1046/j.1365-2265.2000.01000.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  106 in total

1.  Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with polycystic ovary syndrome: a meta-analysis.

Authors:  Song-Tao Tang; Chang-Jiang Wang; Hai-Qin Tang; Wen-Jia Peng; You-Min Wang; Qiu Zhang
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

Review 2.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

3.  Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters.

Authors:  L Sieminska; B Marek; B Kos-Kudla; D Niedziolka; D Kajdaniuk; M Nowak; J Glogowska-Szelag
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 4.  Gender differences in the cardiovascular effect of sex hormones.

Authors:  Cristiana Vitale; Michael E Mendelsohn; Giuseppe M C Rosano
Journal:  Nat Rev Cardiol       Date:  2009-06-30       Impact factor: 32.419

Review 5.  Nonalcoholic fatty liver disease and polycystic ovary syndrome.

Authors:  Evangeline Vassilatou
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 6.  Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child.

Authors:  Ki Park; Janet Wei; Margo Minissian; C Noel Bairey Merz; Carl J Pepine
Journal:  Cardiovasc Drugs Ther       Date:  2015-08       Impact factor: 3.727

7.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

10.  Serum C-reactive protein levels in normal-weight polycystic ovary syndrome.

Authors:  Ji Young Oh; Ji-Ah Lee; Hyejin Lee; Jee-Young Oh; Yeon-Ah Sung; Hyewon Chung
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.